at Zacks.com (Jan 12, 2015)
Teva (TEVA) is facing a bill of up to $2.1B for selling generic versions of Pfizer's (PFE) heartburn drug Protonix before its U.S. patent exclusivity expired in 2011. Teva had already provisioned $670M in Q3 and said this week that the figure could go up by another $1.4B. A trial for Pfizer's claim for damages is due to start in June, while Teva also plans to appeal a jury verdict that upheld Protonix's patent.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 9, 2015)
at CNBC.com (Jan 5, 2015)
at Zacks.com (Dec 31, 2014)
at Nasdaq.com (Dec 31, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs